Intech Investment Management LLC Has $89,000 Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Intech Investment Management LLC grew its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 61.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 58,242 shares of the biotechnology company’s stock after buying an additional 22,254 shares during the period. Intech Investment Management LLC’s holdings in Heron Therapeutics were worth $89,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of HRTX. Y Intercept Hong Kong Ltd acquired a new stake in Heron Therapeutics in the third quarter worth $39,000. Argent Advisors Inc. bought a new position in shares of Heron Therapeutics during the 4th quarter worth about $31,000. Capstone Investment Advisors LLC acquired a new stake in shares of Heron Therapeutics in the 3rd quarter valued at about $45,000. Glenmede Trust Co. NA increased its position in Heron Therapeutics by 49.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 10,578 shares in the last quarter. Finally, Cutter & CO Brokerage Inc. raised its stake in Heron Therapeutics by 69.6% during the 4th quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company’s stock worth $51,000 after buying an additional 13,600 shares during the period. Institutional investors own 80.01% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Needham & Company LLC restated a “buy” rating and set a $4.00 price objective on shares of Heron Therapeutics in a report on Friday, February 28th. StockNews.com downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 8th.

Heron Therapeutics Stock Up 0.9 %

Shares of NASDAQ:HRTX opened at $2.31 on Friday. The business’s 50 day moving average is $1.99 and its 200 day moving average is $1.78. Heron Therapeutics, Inc. has a 12-month low of $1.04 and a 12-month high of $3.93. The stock has a market cap of $351.88 million, a price-to-earnings ratio of -12.83 and a beta of 1.55.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.05. The firm had revenue of $40.78 million for the quarter, compared to analysts’ expectations of $37.37 million. As a group, equities research analysts expect that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.